Global Transdermal Scopolamine Market Size, Share, Growth, Trends, and Forecast 2019-2026

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Transdermal Scopolamine Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Scopolamine Indications
4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.5. Global Transdermal Scopolamine Market Analysis and Forecast, 2018 – 2026
4.5.1. Market Revenue Projections (US$ Mn)
4.6. Porter’s five forces analysis
4.7. Value Chain Analysis
4.8. Market Outlook
4.9. Global Company Share Analysis – 2018 (Estimated)
4.10. Scopolamine Product Prescription Rate by Region (%)
4.10.1. Oral
4.10.2. Injections
4.10.3. Transdermal / Patch
4.11. Pipeline Analysis – Transdermal Scopolamine

Chapter 5. Global Transdermal Scopolamine Market Analysis and Forecasts, By Region
5.1. Key Findings
5.2. Policies and Regulations
5.3. Market Size (US$ Mn) Forecast By Region
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Latin America
5.3.5. Middle East and Africa
5.4. Market Attractiveness By Region

Chapter 6. North America Transdermal Scopolamine Market Analysis and Forecast
6.1. Introduction
6.1.1. Key Findings
6.1.2. Policies and Regulations
6.1.3. Price Trend Analysis
6.1.4. Key Trends
6.2. Market Size (US$ Mn) Forecast, By Country
6.2.1. U.S.
6.2.2. Canada
6.3. Market Attractiveness Analysis By Country

Chapter 7. Europe Transdermal Scopolamine Market Analysis and Forecast
7.1. Introduction
7.1.1. Key Findings
7.1.2. Policies and Regulations
7.1.3. Price Trend Analysis
7.1.4. Key Trends
7.2. Market Size (US$ Mn) Forecast, By Country
7.2.1. Germany
7.2.2. France
7.2.3. U.K.
7.2.4. Spain
7.2.5. Italy
7.2.6. Rest of Europe
7.3. Market Attractiveness Analysis By Country

Chapter 8. Asia Pacific Transdermal Scopolamine Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.1.2. Policies and Regulations
8.1.3. Price Trend Analysis
8.1.4. Key Trends
8.2. Market Size (US$ Mn) Forecast, By Country
8.2.1. Japan
8.2.2. China
8.2.3. India
8.2.4. Australia
8.2.5. Rest of Asia Pacific
8.3. Market Attractiveness Analysis By Country

Chapter 9. Latin America Transdermal Scopolamine Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Policies and Regulations
9.1.3. Price Trend Analysis
9.1.4. Key Trends
9.2. Market Size (US$ Mn) Forecast, By Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Market Attractiveness Analysis By Country

Chapter 10. Middle East & Africa Transdermal Scopolamine Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Price Trend Analysis
10.1.4. Key Trends
10.2. Market Size (US$ Mn) Forecast, By Country
10.2.1. GCC Countries
10.2.2. South Africa
10.2.3. Rest of Middle East and Africa
10.3. Market Attractiveness Analysis By Country

Chapter 11. Competition Landscape
11.1. Transdermal Scopolamine Market – Competition Matrix (By Tier and Size of companies) (2015)
11.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
11.2.1. Baxter International Inc.
11.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.1.2. Product Portfolio
11.2.1.3. SWOT Analysis
11.2.1.4. Financial Overview
11.2.1.5. Strategic Overview
11.2.2. GlaxoSmithKline plc
11.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.2.2. Product Portfolio
11.2.2.3. SWOT Analysis
11.2.2.4. Financial Overview
11.2.2.5. Strategic Overview
11.2.3. Novartis AG
11.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.3.2. Product Portfolio
11.2.3.3. SWOT Analysis
11.2.3.4. Financial Overview
11.2.3.5. Strategic Overview
11.2.4. Perrigo Company plc.
11.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.4.2. Product Portfolio
11.2.4.3. SWOT Analysis
11.2.4.4. Financial Overview
11.2.4.5. Strategic Overview
11.2.5. Caleb Pharmaceuticals, Inc.
11.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.5.2. Product Portfolio
11.2.5.3. SWOT Analysis
11.2.5.4. Financial Overview
11.2.5.5. Strategic Overview
11.2.6. Myungmoon Pharma Co. LTD.
11.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.6.2. Product Portfolio
11.2.6.3. SWOT Analysis
11.2.6.4. Financial Overview
11.2.6.5. Strategic Overview

Chapter 12. Key Take Away